Biotechnology
GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea
YONGIN, South Korea, Feb. 8, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that the World Health Organization (WHO) has awarded prequalification to filling and finish plant onFebruary 3 2023, located in Ochang, South...
ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics Based on ReviR's Comprehensive Approach to RNA-targeted Technologies
SAN FRANCISCO, Feb. 8, 2023 /PRNewswire/ -- ReviR Therapeutics, a privately held developer of a suite of small molecule RNA-targeting technologies for cancer and other genetically-defined diseases, and Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing, an...
SK bioscience Announces the Largest Investment Ever to Establish Songdo Global Research & Process Development Center
* The additional investment for the 'R&PD Center' was confirmed by the board of directors committee with a total of261 million USD * SK bioscience plans to establish a vaccine-biopharmaceutical hub, organizing a global cooperative model against new pandemics SEONGNAM, South Korea, Feb. 8, 202...
Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.
SHANGHAI, Feb. 8, 2023 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx," 688373) announced recently that it has appointedRegis A. Vilchez, MD, PhD, an experienced R&D biopharmaceutical executive and infectious disease expert, as Chief Medical Officer of its American subsidiary, ...
Complete Genomics Drops Genome Sequencing Price to Sub $100 at AGBT General Meeting
DNBSEQ-T20×2*produces up to 50,000 WGS per year at a first sub hundred-dollar price per genome DNBSEQ-T7* offers an outstanding $1.5/Gb price for sequencing consumables DNBSEQ-G99* delivers a first-in-class PE150 run within 12 hours with a data output of 8- 48 Gb per run stLFR library prep ...
RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting
HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 7, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, and together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics today announced ...
J INTS BIO, Oral TKI 'JIN-A04', poster presentation of HER2 exon20 insertion mutation in NSCLC
SEOUL, South Korea, Feb. 6, 2023 /PRNewswire/ -- J INTS BIO announced that the preclinical results of "JIN-A04," a novel oral tyrosine kinase inhibitor (TKI) targeting HER2 Exon20 insertion mutation in NSCLC, will be presented at the upcoming 2023 American Cancer Research Association meeting inOr...
Thermo Fisher Scientific launches Cell Therapy Collaboration Center Program in Singapore to accelerate therapy development across Asia Pacific
Program supports cell therapy innovators in the development of next-generation, life-saving drugs and therapeutics through every stage of their journey to improve patient outcomes SINGAPORE, Feb. 7, 2023 /PRNewswire/ -- Thermo Fisher Scientific Inc., the world leader in serving science, tod...
Tavneos® (avacopan) approved in Australia for the treatment of ANCA-associated vasculitis
First targeted therapy available for the treatment of two main types of ANCA-associated vasculitis (AAV), a rare and systemic disease MELBOURNE, Australia, Feb. 7, 2023 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced the Therapeutic Goods Administration (TGA) i...
Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
WILMINGTON, Del., Feb. 6, 2023 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focusing on developing novel therapeutics for cancers and metabolic diseases, recently announced that the U.S. Food and Drug Administration (FDA) has cleared the company's inves...
Inmagene receives IND clearance for IMG-008, a long-acting IL-36R mAb
SAN DIEGO, SHANGHAI and SYDNEY, Feb. 6, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announced that the U.S. Food and Drug Administration (FDA) recently granted the initial investigational new drug (IND) application for its drug candidate IMG-008, a long-acting anti-IL-36R antib...
Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
* Data from Certa Therapeutics' Phase 2 clinical trial with development candidate FT011 demonstratesclinically meaningful improvements for more than 60 percent of patients with scleroderma after 12 weeks of treatment; * Clinically meaningful improvements were reported in CRISS (the key compos...
Boehringer Ingelheim Philippines is awarded Top Employer for the 5th year in a row
* Boehringer Ingelheim is one of 15 global Top Employers worldwide * Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute® * Outstanding employer benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition M...
Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer
NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointedRoger Sidhu, M.D., as Chief Medical Officer. Dr. Sidhu is a seasoned lea...
Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma
BCMA/CD19 dual-targeting FasTCAR-T GC012F has demonstrated deep responses and favorable safety profile in proof of concept clinical studies Company plans to initiate Phase 1b/2 clinical trial in the U.S. in second quarter of 2023 SAN DIEGO Calif., and SUZHOU and SHANGHAI, China, Feb. 3, 2023 /PR...
Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent
Landmark Agreement for New Tuberculosis Treatment SEONGNAM-SI, South Korea and NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Qurient Co. Ltd. ("Qurient", KRX: 115180), a clinical-stage biotechnology company based inSouth Korea, and TB Alliance, a not-for-profit organization dedicated to the discovery, ...
BriSTAR Immunotech to Present at the BIO CEO & Investor Conference
BEIJING and TORONTO, Feb. 2, 2023 /PRNewswire/ -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today that its Chief Executive Officer,James Pan, Ph.D., will be presenting at the 25th BIO CEO & Investor Conference. The conference will take place at the New York Marriott Mar...
TotalEnergies ENEOS Signs Solar Rooftop Project with Ecolite, a health and wellness company in Malaysia
KUALA LUMPUR, Malaysia, Feb. 2, 2023 /PRNewswire/ -- Ecolite Biotech Manufacturing Sdn Bhd, a health and wellness company inMalaysia, has signed a long-term agreement with TotalEnergies ENEOS to provide a 0.4 megawatt-peak (MWp) solar photovoltaic (PV) system to its facility inMalaysia. Ecolite i...
Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan)
SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Invivoscribe is pleased to announce the appointment ofMasato Sasaki as General Manager of LabPMM GK, our reference laboratory inJapan. Mr. Sasaki brings a wealth of scientific experience with him as he served at Illumina K.K. (Japan) as a leader on their cl...
CN Energy Group. Inc. Announces Closing of $10 Million Underwritten Public Offering
LISHUI, China, Feb. 1, 2023 /PRNewswire/ -- CN Energy Group. Inc. (NASDAQ: CNEY) ("CNEY", or the "Company") today announced the closing of its previously announced underwritten public offering. The gross proceeds to the Company were approximately$10 million, before deducting underwriting discount...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 257 media titles]
2024-05-02 01:21Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 251 media titles]
2024-04-30 15:13